GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
BURLINGTON, Mass., April 07, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. EDT in New York, NY.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T : 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
